Phaseline

Companies › Shanghai Zhimeng Biopharma

Shanghai Zhimeng Biopharma: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Neurology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CB03-154–Phase 2Focal Epilepsy; ALS (Amyotrophic Lateral Sclerosis)Sep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06612775CB03-154Phase 2Focal EpilepsyNeurologySep 2027
NCT07082192CB03-154Phase 2ALS (Amyotrophic Lateral Sclerosis)NeurologySep 2027
NCT07238868CB03-154Phase 2Focal EpilepsyNeurologyJan 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.